Advertisement
Advertisement
U.S. markets close in 4 hours 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

GB Sciences, Inc. (GBLX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0329+0.0062 (+23.41%)
As of 11:12AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0267
Open0.0251
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0251 - 0.0329
52 Week Range0.0200 - 0.0700
Volume158,440
Avg. Volume240,143
Market Cap10.46M
Beta (5Y Monthly)0.13
PE Ratio (TTM)4.71
EPS (TTM)0.0070
Earnings DateAug 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GBLX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GB SCIENCES INC
    Analyst Report: Aurora Cannabis Inc.Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that include Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit

    President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successes Featured Image for GB Sciences Featured Image for GB Sciences LAS VEGAS, May 12, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, discusses the current a

  • GlobeNewswire

    TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference

    President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications. Featured Image for Gb Sciences Featured Image for Gb Sciences LAS VEGAS, May 05, 2022 (GLOBE NEWSWIRE) -- Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (OTCQB:GBLX), a leading plant-inspired biopharmaceutical research and development company, spoke

  • GlobeNewswire

    FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies

    Plant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome. COVID Research COVID Research LAS VEGAS, May 02, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, announces that FHI Clinical Inc. will consult on Gb Sciences' go-to-market strategy for its COVID-19-rel

Advertisement
Advertisement